Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sigvotatug Vedotin vs Docetaxel in Previously Treated NSCLC (BE6A LUNG-01)
NCT06012435Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Feb 2024
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 25
01
Overview
A Phase 3 trial of sigvotatug vedotin in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Feb 2024; status: active, not recruiting.
02
Drugs
sigvotatug vedotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06012435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06012435.